Clinical Trial Update: Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BHV-7000 as monotherapy for Major depressive disorder has completed, with efficacy and safety results reported in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• BHV-7000

Snippet

Sponsor: Biohaven Therapeutics Ltd. | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED